ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2185 entries already.
Two listed Scandinavian biotech companies are about to merge into one. Medical Prognosis Institute A/S (Nasdaq First North Stockholm) in Denmark and Oncology Venture Sweden AB (Aktie Torget) in Sweden aim to create what they call a one-stop-shop for personalised cancer treatments.
The 33rd edition of Chemspec Europe, International Exhibition for Fine and Speciality Chemicals, ended after two successful show days with record visitor numbers. From 20 to 21 June 2018, a total of 4,202 trade visitors came to the exhibition grounds of the Koelnmesse in Cologne, Germany, where international experts of the fine and speciality chemicals industry met for Europe’s leading exhibition. These figures represent an increase of visitor numbers by nearly 9% compared to last year’s show in Munich.
Researchers at VTT Technical Research Centre of Finland have developed a vaccine, diluted into drinking water, to treat diarrhoea on piglets being weaned. The vaccine is expected to reduce the global resistance problem caused by excessive antibiotic use.
In Brussels, European Commissioners Jyrki Katainen and Carlos Moedas proposed a budget increase of 25% for the next European Research and Innovation programme Horizon Europe (2021-27) compared to Horizon 2020. Insummer, however, the EC’s High LevelGroup recommended a budget of at least €120bn.
VarmX will use the combination of a €7.5m Series A financing co-led by BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter plus an €5m innovation credit from the Netherlands Enterprise Agency (RVO.nl) to develop a modified blood coagulation factor X to prevent severe bleeding in haemophilia patients.
The EMA’s CHMP recommended nine medicines including six orphan medicines for EU market approval on Friday.
German and US researchers have designed a mouse model that exactly mimics the mechanisms of hepatitis infection in men.
Agribiotech lobby group ISAAA reports that global GMO acreage has grown to 189.8 million hectares in 2017 -3% or 4.7 million hectares more than in 2016.
Roche’s Japanese arm Chugai today returned all rights from a 2016 licence agreement on the RNA polymerase II blocker lurbinectedin to Spanish oncology specialist PharmaMar SA.
How do novel technologies affect the world’s largest enzyme producer? At the GBS, European Biotechnology asked Thomas Videbaeck, PhD, COO and Executive VP Research, Innovation and Supply.